Last reviewed · How we verify
CGC-11047 and docetaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CGC-11047 and docetaxel (CGC-11047 and docetaxel) — Progen Pharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CGC-11047 and docetaxel TARGET | CGC-11047 and docetaxel | Progen Pharmaceuticals | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CGC-11047 and docetaxel CI watch — RSS
- CGC-11047 and docetaxel CI watch — Atom
- CGC-11047 and docetaxel CI watch — JSON
- CGC-11047 and docetaxel alone — RSS
Cite this brief
Drug Landscape (2026). CGC-11047 and docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/cgc-11047-and-docetaxel. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab